Mdxhealth’s molecular diagnostic solutions address a significant unmet medical need for timely, actionable information that addresses the challenges of the current standard of care for diagnosing prostate cancer. Our tests help identify patients at increased risk for aggressive prostate cancer, thereby aiding in the selection of men for prostate biopsy.
A highly predictive urine test to help identify men at risk for aggressive prostate cancer prior to initial biopsy.
A tissue test to improve the identification of men at risk for undetected clinically significant prostate cancer after a negative biopsy.
Science & Technology
Mdxhealth has a proprietary portfolio of biomarkers and bioinformatic technologies from which it develops and commercializes state-of-the-art diagnostic, prognostic and predictive tests for urologic oncology.